BioSpace News Archive

Biotech Bay

Adverum Biotechnologies to Participate in Upcoming May 2024 Investor Conferences

Adverum Biotechnologies, Inc., a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, announced that the company will present at the following upcoming investor conferences.

May 3, 2024
·
1 min read
Drug Development

PDS Biotechnology Announces Details of Virtual KOL EventVirtual Webinar Updated VERSATILE-002 Phase 2 Trial Results, Unmet Treatment Needs in Advanced Head and Neck Cancer and Planned Triple Combination Trial to be held May 8, 2024

PDS Biotechnology Corporation announced additional details of its virtual Key Opinion Leader event to be held on Wednesday, May 8, 2024 at 1:30 PM ET.

May 3, 2024
·
10 min read
Pharm Country

Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024

Johnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024.

May 3, 2024
·
8 min read
Business

Lykos Therapeutics Strengthens Commercial Organization with Key Hires as it Prepares for Potential Commercial Launch

Lykos Therapeutics announced Allison Rosenthal has been appointed Chief Commercial Officer (CCO) and member of the Company’s executive committee effective immediately.

May 3, 2024
·
3 min read
Business

Probo Medical Hires Greg Kopulos and Ashlyn Jennings

Probo Medical has announced the hiring of two new executives to their executive team, Greg Kopulos and Ashlyn Jennings, to support the continued growth of the company.

May 3, 2024
·
1 min read
Deals

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 3, 2024

Insmed Incorporated today announced the granting of inducement awards to 63 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed’s Compensation Committee.

May 3, 2024
·
2 min read
Pharm Country

Avantor® to Participate in BofA Securities 2024 Health Care Conference

Avantor, Inc. announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the BofA Securities 2024 Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at approximately 10:00 a.m. Pacific Time.

May 3, 2024
·
1 min read
Drug Development

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).

May 3, 2024
·
6 min read
Deals

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 3, 2024

Viridian Therapeutics, Inc. today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 551,000 shares of the company’s common stock.

May 3, 2024
·
2 min read
Lone Star Bio

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer

Natera, Inc. today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease.

May 3, 2024
·
5 min read